Pinealon is a very short synthetic peptide built from three amino acids (Glu-Asp-Arg, EDR for short). It comes from the school of “peptide bioregulators” developed since the 1990s at the Saint Petersburg Institute of Bioregulation and Gerontology, and it is sometimes sold as a “brain peptide” that is supposed to protect neurons and support memory. The scientific literature is real but narrow: a dozen or so papers on cells and rodents plus two small observations in people, almost all from a single research network. No randomised, placebo-controlled trial has ever been published, and the ClinicalTrials.gov register lists no study of this compound at all.
What Pinealon is
Pinealon is the trade name of a Russian preparation from the group of so-called cytogens — short peptides that, according to their originators, “regulate” the work of specific tissues. The compound itself is the tripeptide EDR: glutamic acid, aspartic acid and arginine joined into one small chain. The name evokes the pineal gland, but in the scientific papers the peptide simply appears as a synthetic tripeptide, not as an extract of any organ. The same family includes KED (Lys-Glu-Asp) and AEDG, better known as Epitalon; in the Saint Petersburg papers EDR is usually studied alongside them and compared with them.
The originators describe EDR as an “epigenetic regulator” — a molecule supposed to influence which genes in a cell are read. A review by the same group (Khavinson et al., 2020) credits the peptide with activating genes that keep neurons working, inhibiting apoptosis (programmed cell death) and protecting dendritic spines, the tiny protrusions on which neurons form their connections. Below we check what part of that list is backed by studies.
How it is meant to work — no receptor, but DNA
A typical peptide acts through a receptor — a “switch” on the cell surface that starts a signal inside. No such receptor has been described for Pinealon. Instead an unusual mechanism is proposed: the peptide is meant to enter the cell and its nucleus and bind there directly to DNA, or to the proteins that package DNA (histones), and in that way change how genes are read.
The idea rests on physical-chemistry and computational work. An independent group from the physics faculty of Saint Petersburg State University (Silanteva et al., 2019) showed by spectral methods, NMR, viscometry and molecular dynamics that EDR can partly enter the major groove of DNA and act on guanine atoms, and that magnesium ions favour this binding. It is one of the few papers on this peptide from outside the originating network — but it only shows that the peptide can “touch” DNA in a test tube, not that this changes how genes work in a living brain.
The second pillar is computer modelling: in the mouse study (Khavinson et al., 2021) EDR was docked against all 2,080 possible six-nucleotide DNA fragments, and the energetically most favourable sequences were found in the control regions of genes linked to Alzheimer's disease, including CASP3, APOE, SOD2, PPARA and PPARG. These are calculations, not measurements in a cell; the authors themselves write in their 2020 review that EDR “probably” binds histones or RNA. The mechanism remains a hypothesis.
What was studied — cells
The most-cited result concerns oxidative stress. In cultures of rat cerebellar granule cells, neutrophils and PC12 cells, Pinealon restricted the accumulation of reactive oxygen species (free radicals) in a concentration-dependent way and reduced the share of cells dying by necrosis (Khavinson et al., 2011). The effect went together with delayed activation of the ERK1/2 pathway and changes in the cell cycle, which the authors took as a sign that the peptide “interacts directly with the genome”.
The second result concerns dendritic spines. In a culture of mouse hippocampal neurons exposed to toxic amyloid (an Alzheimer's model in a dish), EDR at 200 ng/ml increased the number of mushroom spines — regarded as “memory spines” — by 71 % and returned it to the control level, while the peptide KED gave only 20 % (Kraskovskaya et al., 2017). An erratum has been published for that paper.
The most recent paper (Kraskovskaya et al., 2024) used a more interesting model: skin fibroblasts from elderly donors were reprogrammed into cortical neurons that keep the donor's “age”. EDR, KED and AEDG increased the branching of the dendritic tree, and EDR additionally reduced oxidative DNA damage. They did not change the activity of mitochondria and lysosomes or the level of the p16 protein, a marker of cell ageing. It is still a dish, though one with human cells.
What was studied — animals
The only study with a living model of Alzheimer's disease used transgenic 5xFAD mice (Khavinson et al., 2021): 10 animals per group, peptides injected intraperitoneally every day from 2 to 4 months of age. EDR increased the density of dendritic spines in the CA1 field of the hippocampus by 11 % (p = 0.039) and returned it to the level of healthy mice, but did not change the share of mushroom spines, and in the measure of synaptic plasticity (LTP) it gave only a trend without statistical significance. An erratum was published for this paper too — two figures turned out to be identical; the authors stood by their conclusions.
An earlier study (Arutjunyan et al., 2012) concerned pregnant rats fed excess methionine, which raises homocysteine and harms the offspring's brain. Pinealon given to the mothers improved the young animals' spatial orientation and learning and reduced the amount of free radicals and the number of necrotic neurons in their cerebellum.
Human data — what was really studied
PubMed contains not a single randomised, blinded, placebo-controlled trial of Pinealon, and the ClinicalTrials.gov register has no entry for this compound (as of September 2026). Everything that exists in people consists of small, open observations published in Russian, in which Pinealon was given together with another peptide (Vesugen) — so it is not even possible to say which of the two accounts for what.
The most concrete is the study by Meshchaninov et al. (2015): 32 people (18 men, 12 women) aged 41–83 with multiple chronic diseases and organic brain syndrome in remission. The authors describe a “significant anabolic effect” and improved biological-age indicators, with Vesugen doing better than Pinealon. More interesting are the side findings: chemiluminescence showed a pro-oxidant action (the opposite of the “antioxidant” effect seen in cell cultures), and the share of CD34+ cells in the blood fell, which the authors read as inhibition of blood-cell formation. There was no placebo group and no randomisation.
The second study (Bashkireva and Artamonova, 2012) comes from occupational medicine: 150 lorry drivers were compared with 150 metalworkers for neurotic disorders, and some participants were given bioregulating peptides. The authors report improved psycho-emotional indices and resistance to work stress (p from 0.05 to 0.001), best when Pinealon was combined with Vesugen. PubMed tags the paper as a clinical trial, but the abstract mentions no placebo, no blinding and no figures for Pinealon alone. That is all the literature says about people.
What Pinealon does not do — the mix-up with Epitalon
Vendor descriptions credit Pinealon with “telomerase activation” and “telomere lengthening”. PubMed has not a single paper linking Pinealon (or EDR) with telomerase. All the telomerase papers in this family concern a different peptide of the same school — the tetrapeptide AEDG, known as Epitalon. Transferring those results to Pinealon is a factual error, not shorthand: it is a different molecule, studied in different models.
Safety and the limits of the evidence
Almost nothing is known about the safety of Pinealon. A PubMed search for “pinealon” together with toxicity returns not a single paper — there are no genotoxicity, carcinogenicity or chronic-toxicity studies. That gap is particularly awkward for a compound whose own originators credit it with influencing how genes are read: the stronger the claim about acting on DNA, the more one needs data on whether it does something unwanted there.
The only human observations (Meshchaninov et al., 2015) gave two warning signals: a pro-oxidant effect and a fall in CD34+ cells in the blood. The same paper reports that the peptides did not change the degree of chromatin condensation, which the authors took as a sign of safety at the level of the cell nucleus — with 32 people and no placebo that is a single observation, not proof.
Almost the entire literature comes from one research network (the Saint Petersburg Institute of Bioregulation and Gerontology and its partners), so the results have not been independently replicated. Pinealon is not registered as a medicine: it appears neither in the Polish Register of Medicinal Products nor in the FDA drug database. We deliberately give no methods of use and no doses.
The wider context — peptide bioregulators
Pinealon belongs to a family of short peptides that Russian gerontology calls bioregulators: alongside EDR there are KED, AEDG (Epitalon) and a dozen other three- and four-letter abbreviations. They share the same pattern: a rich literature from one centre, results on cells and rodents, and no phase 2 or phase 3 clinical trials in the sense used by Western drug agencies.
For comparison it is worth looking at a neurological preparation that did go down that road: Cerebrolysin is a mixture of peptides from pig brain, holds a medicine authorisation in Poland among other countries, and has been through large randomised trials and Cochrane reviews. The results there are ambiguous, but at least they exist. For Pinealon that material simply does not exist.
Summary
Pinealon is the three-amino-acid peptide EDR, which its originators credit with regulating gene readout without any receptor. The evidence is arranged in the reverse order to drug development: strongest in cells (fewer free radicals, more dendritic spines, more branching in neurons derived from elderly donors' cells), weaker in rodents (spine density +11 % in 5xFAD mice, no significant gain in synaptic plasticity), and in people it comes down to two small, open observations with peptides given in combination — one of which showed a pro-oxidant signal and a fall in CD34+ cells.
Two more things need saying plainly: telomerase belongs to Epitalon, not to Pinealon, and there are no toxicity data at all. On today's evidence Pinealon is an interesting research object with an unestablished mechanism and an unknown safety profile, not a proven neuroprotective agent.
Sources
- Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. Advances in Gerontology (Uspekhi Gerontologii). 2015;28(1):62-67. PMID: 26390612. pubmed.ncbi.nlm.nih.gov/26390612
- Bashkireva AS, Artamonova VG. [The peptide correction of neurotic disorders among professional truck-drivers]. Advances in Gerontology (Uspekhi Gerontologii). 2012;25(4):718-728. PMID: 23734521. pubmed.ncbi.nlm.nih.gov/23734521
- Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2021;14(6):515. PMID: 34071923. DOI: 10.3390/ph14060515. pubmed.ncbi.nlm.nih.gov/34071923
- Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine. 2012;5(2):179-185. PMID: 22567179. pubmed.ncbi.nlm.nih.gov/22567179
- Kraskovskaya NA, Kukanova EO, Lin'kova NS, Popugaeva EA, Khavinson VK. Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease. Bulletin of Experimental Biology and Medicine. 2017;163(4):550-553. PMID: 28853087. DOI: 10.1007/s10517-017-3847-2. pubmed.ncbi.nlm.nih.gov/28853087
- Kraskovskaya N, Linkova N, Sakhenberg E, et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences. 2024;25(21):11363. PMID: 39518916. DOI: 10.3390/ijms252111363. pubmed.ncbi.nlm.nih.gov/39518916
- Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011;14(5):535-541. PMID: 21978084. DOI: 10.1089/rej.2011.1172. pubmed.ncbi.nlm.nih.gov/21978084
- Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA. Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. The Journal of Physical Chemistry B. 2019;123(9):1896-1902. PMID: 30762356. DOI: 10.1021/acs.jpcb.8b10359. pubmed.ncbi.nlm.nih.gov/30762356
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020;26(1):159. PMID: 33396470. DOI: 10.3390/molecules26010159. pubmed.ncbi.nlm.nih.gov/33396470
For in-vitro laboratory research only. It is not a human medicine and is not for treatment.